PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
13-Jul-2022 PharmiWeb.Jobs Welcomes Excelya PharmiWeb.Jobs
12-Jul-2022 Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa Endogena Therapeutics
12-Jul-2022 No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1 Novo Nordisk
12-Jul-2022 Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 Novo Nordisk
12-Jul-2022 Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Sanofi
12-Jul-2022 Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis Sanofi
08-Jul-2022 FDA Releases Draft Guidance on CMC For Individualized ASO Therapies SAE Media Group
06-Jul-2022 Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 HUTCHMED
04-Jul-2022 Innovative Trials acquires first US office as part of mission to support patient access to clinical trials Innovative Trials
04-Jul-2022 CD Bioparticles Expands Lipid System Portfolio by the Launch of Sphingolipids CD Bioparticles
04-Jul-2022 CD Bioparticles Announces the Launch of Colored Polystyrene Particles CD Bioparticles
04-Jul-2022 Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research Creative Diagnostics
30-Jun-2022 Santhera Updates on Ongoing NDA Submission for Vamorolone Santhera
30-Jun-2022 Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856 MAD
30-Jun-2022 NICE publishes FAD recommending the use of Adtralza®▼(tralokinumab) NICE
30-Jun-2022 Phacilitate announces the inauguration of First Gala Awards Dinner to celebrate the achievements of the advanced therapies field Phacilitate
30-Jun-2022 Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer Amolyt Pharma 
30-Jun-2022 Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
30-Jun-2022 International Centers for Precision Oncology International Centers for Precision Oncology
29-Jun-2022 PHASTAR Names Chris Schoonmaker as Chief Operations Officer PHASTAR